Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date

Rebecca Howell,1 Adrienne M Wright,1 Jennifer N Clements2 1Presbyterian College School of Pharmacy, Clinton, SC 29325, USA; 2Department of Pharmacy Practice, Presbyterian College School of Pharmacy, Clinton, SC 29325, USA Abstract: Metformin is the first-line therapy for the management of type 2 dia...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Howell R, Wright AM, Clements JN
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	glucagon-like peptide-1 glucagon-like peptide-1 receptor agonist liraglutide cardiovascular Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/418b5a932ce94726935dae48e2b6e826
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:418b5a932ce94726935dae48e2b6e826
record_format	dspace
spelling	oai:doaj.org-article:418b5a932ce94726935dae48e2b6e8262021-12-02T07:19:00ZClinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date1178-7007https://doaj.org/article/418b5a932ce94726935dae48e2b6e8262019-04-01T00:00:00Zhttps://www.dovepress.com/clinical-potential-of-liraglutide-in-cardiovascular-risk-reduction-in--peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Rebecca Howell,1 Adrienne M Wright,1 Jennifer N Clements2 1Presbyterian College School of Pharmacy, Clinton, SC 29325, USA; 2Department of Pharmacy Practice, Presbyterian College School of Pharmacy, Clinton, SC 29325, USA Abstract: Metformin is the first-line therapy for the management of type 2 diabetes. After 3 months of metformin, add-on therapy can be considered if an individual’s glycemic control has not been achieved for hemoglobin A1c, fasting blood glucose levels, and postprandial blood glucose levels. Liraglutide is a potential second-line option for the management of type 2 diabetes mellitus, particularly for those who are or may be at a high risk of cardiovascular disease. It can also be used an add-on therapy for those individuals with established cardiovascular disease. Liraglutide has additional benefits, such as no to minimal risk of hypoglycemia and promotion of weight loss through its mechanism of action. This particular article summarizes evidence on cardiovascular biomarkers and surrogate endpoints, along with macrovascular events, with liraglutide therapy. Overall, liraglutide has extensive cardiovascular evidence based on which it could be used as a desirable agent for glycemic control while lowering the risk of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and hospitalization from heart failure. Keywords: glucagon-like peptide-1, glucagon-like peptide-1 receptor agonist, liraglutide, cardiovascularHowell RWright AMClements JNDove Medical Pressarticleglucagon-like peptide-1glucagon-like peptide-1 receptor agonistliraglutidecardiovascularSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 12, Pp 505-512 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	glucagon-like peptide-1 glucagon-like peptide-1 receptor agonist liraglutide cardiovascular Specialties of internal medicine RC581-951
spellingShingle	glucagon-like peptide-1 glucagon-like peptide-1 receptor agonist liraglutide cardiovascular Specialties of internal medicine RC581-951 Howell R Wright AM Clements JN Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date
description	Rebecca Howell,1 Adrienne M Wright,1 Jennifer N Clements2 1Presbyterian College School of Pharmacy, Clinton, SC 29325, USA; 2Department of Pharmacy Practice, Presbyterian College School of Pharmacy, Clinton, SC 29325, USA Abstract: Metformin is the first-line therapy for the management of type 2 diabetes. After 3 months of metformin, add-on therapy can be considered if an individual’s glycemic control has not been achieved for hemoglobin A1c, fasting blood glucose levels, and postprandial blood glucose levels. Liraglutide is a potential second-line option for the management of type 2 diabetes mellitus, particularly for those who are or may be at a high risk of cardiovascular disease. It can also be used an add-on therapy for those individuals with established cardiovascular disease. Liraglutide has additional benefits, such as no to minimal risk of hypoglycemia and promotion of weight loss through its mechanism of action. This particular article summarizes evidence on cardiovascular biomarkers and surrogate endpoints, along with macrovascular events, with liraglutide therapy. Overall, liraglutide has extensive cardiovascular evidence based on which it could be used as a desirable agent for glycemic control while lowering the risk of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and hospitalization from heart failure. Keywords: glucagon-like peptide-1, glucagon-like peptide-1 receptor agonist, liraglutide, cardiovascular
format	article
author	Howell R Wright AM Clements JN
author_facet	Howell R Wright AM Clements JN
author_sort	Howell R
title	Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date
title_short	Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date
title_full	Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date
title_fullStr	Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date
title_full_unstemmed	Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date
title_sort	clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/418b5a932ce94726935dae48e2b6e826
work_keys_str_mv	AT howellr clinicalpotentialofliraglutideincardiovascularriskreductioninpatientswithtype2diabetesevidencetodate AT wrightam clinicalpotentialofliraglutideincardiovascularriskreductioninpatientswithtype2diabetesevidencetodate AT clementsjn clinicalpotentialofliraglutideincardiovascularriskreductioninpatientswithtype2diabetesevidencetodate
_version_	1718399513448677376

Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date

Ejemplares similares